Abstract. We carried out a seroepidemiologic survey to define the prevalence of human T cell lymphotropic virus types 1/2 (HTLV-1/2) infections among aboriginal populations from isolated regions of northern Argentina and the Amazon region of Peru. Antibodies against HTLV were measured with agglutination tests and confirmed with by an immunofluorescence assay (IFA) and Western blotting. Five (6.94%) of 72 samples from the Tobas Indians in Argentina were positive by the IFA; two samples were typed as HTLV-1 (2.78%), two as HTLV-2 (2.78%), and one (1.39%) could not be typed because it had similar antibody titers against both viruses. No positive samples were found among 84 Andinos Puneños and 47 Matacos Wichis Indians. Seroprevalences of 2.50% (1 of 40) and 1.43% (1 of 70) for HTLV-1 were observed among Wayku and San Francisco communities in the Amazon region of Peru, and seroprevalences of 4.54% (1 of 22) and 2.38% (1 of 42) for HTLV-2 were observed among Boca Colorada and Galilea communities. No serologic evidence of human immunodeficiency virus (HIV) infection was found among the Indians tested. These results indicated the presence of HTLV-1 and HTLV-2 in the indigenous populations of Argentina and Peru. Moreover, the lack of HIV infection indicates that the virus has probably not yet been introduced into these populations.
Human T cell lymphotropic virus type 1 (HTLV-1) is the etiologic agent of adult T cell leukemia, as well as a chronic paralytic neurologic disease known as HTLV-1-associated myelopathy or tropical spastic paraparesis (HAM/TSP). 1 Unlike HTLV-1, HTLV-2 has not yet been firmly associated with any disease, although recent reports have linked HTLV-2 with neurologic and hematologic illness in small numbers of patients. 2, 3 Epidemiologic studies have demonstrated that HTLV-1 is distributed around the world, but in geographically clustered areas. 4 More interestingly, HTLV-1 and HTLV-2 have been identified in several aboriginal Indian populations in the Americas. 4, 5 New World Indian tribes in which an elevated prevalence of HTLV-2 has been reported include the Guaymi tribe of Panama, 6 the Athapaskan and Pueblo groups of the southwestern United states, 7 the Ge-speaking tribes of Amazonia, 8 Florida Indians, 9 the Wayuu 10 and Tunebo Indians of Colombia, 11 and the Tobas of Bolivia and Paraguay. 12 Recently, a high rate of infection with HTLV-2 has been reported in Indian populations from Argentina. 13 Established risk factors for HTLV-1/2 infection are extremely rare in these populations.
In Peru, initial data linked HTLV-1 infection with TSP patients born in the Andean Trapeze region. 14 Subsequently, survey data indicated the presence of HTLV-1 infection among female sex workers in Callao, Lima, and Iquitos 15, 16 and in the Quechua Ameridian group in Cuzco and Quillabamba. 17 There have been no previously published reports of HTLV-1/2 infection and disease association in the isolated Amazon communities of Peru.
To gain greater insight into the scope of HTLV-1/2 infection in the isolated aboriginal communities of Peru and Argentina, we carried out a seroepidemiologic survey to determine HTLV-1/2 prevalence, identify modes of transmission, and analyze demographic risk factors and patterns of clustering of infected persons.
MATERIALS AND METHODS

Study population.
Only those subjects who provided informed consent for blood collection were enrolled in the study. The studies were conducted in both countries with approval of the Local Medical and Government authorities and with the consent of Aboriginal Organizations. The sample size was estimated based on the actual number of inhabitants in each Indian community studied (according to the Aboriginal Organization census) and a 95% confidence level.
Indian population of Argentina. Two hundred three members belonging to three Indian communities from different areas in northern Argentina were examined (Table 1 and Figure 1 ). These populations have little contact with non-Indian groups and reside in remote, isolated areas. Basic demographic data, including name, age, sex, and family relationships from each participant were obtained by interview of adults. The volunteers included 104 women and 99 men whose ages ranged from six to 80 years with a mean age of 33.14.
Venous blood was obtained for serologic studies. The serum samples from the Andinos Puneños community were collected between February and March 1995, while Tobas and Matacos samples were obtained in 1985. All specimens were stored at Ϫ70ЊC until HTLV-1/2 antibody testing was conducted and were frozen a maximum of two times. All serum samples were previously tested for Chagas' disease and Brucella infections (Serra H, unpublished data).
Indian populations of the Amazon region of Peru. Four hundred fifty-six sera collected between July and October Figure 2 ). The serum samples were stored kept at Ϫ20ЊC until antibody testing could be performed. Epidemiologic data regarding hepatitis B virus, hepatitis D virus, and retrovirus infections, as well as basic demographic data, were obtained. The names and identifying number of aboriginals from whom samples were obtained were recorded with the translation assistance of the Interethnic Association for the Development of the Amazon Region of Peru (Lima, Peru). The volunteers included 218 women and 238 men whose ages ranged between one and 77 years with a mean age of 22.7. All serum samples have been previously tested for hepatitis B and D virus markers (Cabezas C, unpublished data).
Laboratory methods. Serum specimens were tested for HTLV-1/2 antibodies by a particulate agglutination (PA) technique (Serodia; Fujirebbio, Inc., Tokyo, Japan) and by an immunofluorescence assay (IFA) using the HTLV-1 and HTLV-2 transformed human T cell lines MT-2 and Mo-T, respectively. 19 The IFA titration was used to differentiate HTLV-1 and HTLV-2 antibodies. Specimens reactive in the PA technique and IFA were also tested by an HTLV Western blot (Problot-HTLV-1; Fujirebbio, Inc).
Sera were also tested for antibodies against human immunodeficiency virus type-1 (HIV-1) with the PA technique to investigate the overall burden of retrovirus infection in these semi-isolated indigenous group. The HTLV-1/2 reference serum samples, which were provided by the Center for Disease Control and Prevention (Atlanta, GA), were used as control specimens in each assay.
Positivity criteria for HTLV-1/2 antibody detection.
All the samples reactive in the PA technique were confirmed by IFA and Western blotting. The criterion for positivity in the IFA was a focal cytoplasmic pattern and/or capping staining without nuclear staining. A specimen with reactivity to both env-encoded glycoprotein and gag-encoded protein in the Western blot was considered positive for HTLV-1/2 antibodies. A specimen was considered indeterminate if it showed any other band patterns that did not meet the criteria for positivity. Statistical analysis. Analysis of the data was performed using the chi-square and Fisher's exact tests to compare the seroprevalence rates of the various Indian groups.
RESULTS
Prevalence of HTLV-1/2 antibodies in Indian populations of Argentina. Table 3 shows the results obtained with the various methods used. Seven (3.45%) of the 203 samples studied were repeatedly reactive to HTLV-1/2 antigens by the PA technique. Of these, five (2.46%, 95% confidence interval ϭ 0.40-4.59) were confirmed by both Western blotting and the IFA.
Five (6.94%, 95% confidence interval ϭ 0.90-12.90) of 72 samples were positive among the Tobas Indians by the IFA; two samples were typed as HTLV-1 (2.78%), two as HTLV-2 (2.78%), and one (1.39%) could not be typed because it had similar antibody titers against both viruses. Of the five positive cases, three were women between 23 and 31 years of age and two were males 39 and 66 years old, respectively. No positive samples were found among 84 Andinos Puneños and 47 Matacos-Wichis Indians. None of the 203 Indian people tested in the region showed HIV-1 seroreactivity. Prevalence of HTLV-1/2 antibody among distinct aboriginal groups inhabiting the Amazon region of Peru. These results are shown in Table 4 . Of the 456 individuals tested, four (0.88%) were confirmed by both IFA and Western blotting. Two of the positive individuals were infected with HTLV-2 and two were infected with HTLV-1, as determined by differential IFA titration, giving overall HTLV-1 and HTLV-2 seroprevalences of 0.44% and 0.44%, respectively. Of the four positive cases, two were women and two were men more than 24 years of age. Seroprevalences for HTLV-1 of 2.50% (1 of 40) and 1.43% (1 of 70) were observed among the Wayku and San Francisco de Asis communities, respectively, while seroprevalences for HTLV-2 of 4.54% (1 of 22) and 2.38% (1 of 42) among the Boca Co- * Antibody titers are expressed as the inverse of the highest serum dilution that showed a positive reaction. Titers Ն 4 were considered significant. P ϭ expected frequency computed by a Poisson distribution. lorada and Galilea communities, respectively. Because the number of subjects with HTLV-1/2 antibodies in these groups was Ͻ 5, the estimated prevalences are consistent with the expected frequency of positive individuals computed by a Poisson distribution ( Table 4) . None of the 456 Peruvian aboriginal serum samples showed HIV-1 seroreactivity. The difference in HTLV-1/2 seroprevalences among the distinct Indian communities was not statistically significant.
DISCUSSION
Infection with HTLV-1/2 has been reported in a number of aboriginal Indians from various geographic regions of the Americas. 4, 5 With the exception of the reported HTLV-2 endemic infection in Indians from Argentina, 13, 20 there are no other confirmed reports of HTLV-1/2 infection in the aboriginal Indians from the Amazon region of Peru.
We confirmed the endemic circulation of HTLV-1/2 among the Tobas Indians of Argentina, which showed a prevalence of 6.94%. Moreover, these are the first Peruvian aboriginal Indians from the Amazon region reported to have HTLV-1/2 infections (0.88%). The serologic results presented clearly demonstrate that both HTLV-1 and HTLV-2 were present among these aboriginal populations in both countries.
In Argentina, the previously estimated HTLV-1/2 seroprevalence among blood donors was lower (0.10%) than the range of seroprevalences we measured in the Tobas Indians in this study (HTLV-1 ϭ 2.78%, HTLV-2 ϭ 2.78%, HTLV-1/2 ϭ 1.39%). This indicates that infection by these retroviruses in these aboriginal Indians seems to have an endemic distribution. 21 The lack of HTLV-1/2 infections in the Andinos Puneños and the Matacos Indians suggests that the virus had not spread significantly in these populations and circulates with a very low prevalence.
Only a few studies have demonstrated the presence of HTLV-1 in Amerindians. 10, 17 Several studies have indicated the presence of HTLV-2 in Matacos and Tobas Indians from Argentina and the Atacama population from Chile. 13, 20, 22 The seroprevalences of HTLV-1 and HTLV-2 among the Indians of the Amazon region of Peru studied were comparable (0.44% versus 0.44%). Moreover, our finding is the first reported with regard to the presence of HTLV-2 in these aboriginal populations. Recently, the presence of HTLV-1 (5.10%) without HTLV-2 was reported in the Quechua group of Peru. 17 The lack of specific HTLV-2 seroreactivity previously reported by Zurita and others 17 raises questions concerning the adequacy of HTLV-1-based assays for detecting HTLV-2-infected patients. This is important from a diagnostic and epidemiologic point of view since it may led to a misdiagnosis of HTLV-2 infection. Therefore, it may be necessary to use differential product-type assays to determine whether HTLV-1 or HTLV-2 is present.
All the Argentinian and Peruvian Indians who were HTLV-1/2 positive were more than 23 years of age, were natives from the region where they resided, and belonged to isolated communities with homogeneous racial and behavioral characteristics. They were identified in the Tobas tribes in northeastern Argentina, and in the Galilea, San Francisco, Boca Colorada, and Wayku communities in Santiago, and the Ucayali, Madre de Dios, and Mayo River basins in Peru. No retroviral risk factors such as blood transfusion, intravenous drug addiction, or surgery were found, and the seropositive samples were obtained from subjects that reported only one sexual partner. The HTLV-1/2-positive aboriginal Indians from both Argentina and Peru were asymptomatic carriers.
The origin of the virus that led to the HTLV-1/2 infections in these Indians is unknown. The role of sexual transmission of HTLV-1/2 among this cohort does not seem to be important since no serologic evidence of other sexually transmitted infections such as hepatitis B virus, hepatitis C virus, and HIV, was found among the HTLV-1/2-seropositive Indians tested. However, a high prevalence of hepatitis B virus and hepatitis D virus infections were observed among the indigenous population, as well as among settlers throughout the various Peruvian Amazon basins (Cabezas C, unpublished data). It is important to note that the lack of HIV infection indicates that the virus has probably not yet been introduced in these populations. Previous studies have not found any serologic evidence of sexually transmitted infections with the spirochete Treponema pallidum, hepatitis B virus, hepatitis C virus, and HIV among the Tobas Indians. 13 Although Chagas' disease is endemic among the Tobas and Matacos Indians (prevalence ϭ 37.50% and 50%, respectively, Serra H, unpublished data), none of the HTLV-1/2-positive sera showed Chagas' disease-specific seroreactivity.
Since the majority of the aboriginal mothers breast-feed their infants, this practice may have been a source of HTLV-1/2 infections. Several studies have indicated that the peculiar endemicity of HTLV-1 depends mainly on variables associated with mother-to-child transmission. 23, 24 The absence of significant differences in the prevalence among male (in Argentina: 2.02%; in Peru: 0.84%) and female (in Argentina: 2.88%; in Peru: 0.91%) Indians supports this hypothesis suggesting that most carriers were maternally rather than sexually infected, since it has been reported that there is a higher prevalence of infection in females than in males among sexually active populations. 23 Nevertheless, since this work is currently limited by its cross-sectional design and insufficient behavioral data, we cannot rigorously exclude the possibility that the HTLV-1/2 infections we are currently observing originated from sources outside the Indian communities. However, we believe this is unlikely because the Indian populations studied have little contact with non-Indian groups and reside in remote, isolated areas. Our findings also support the hypothesis that HTLV-1/2 infections are less efficiently transmitted than other horizontally transmitted viruses, which show a lower infection rate over time in these communities.
Interfamilial and intrafamilial epidemiologic and molecular studies of HTLV-1 and HTLV-2 in these Amerindian communities may further clarify the factors governing viral transmission, the natural history of infection, as well as the emergence, dissemination, and evolution of these retroviruses. Laboratory, molecular, epidemiologic, and behavioral studies associated with HTLV-1/2 infections among isolated communities are in progress.
